

Chairpersonship of Shri Arun Maira, Member (Industry), Planning Commission to consider all the relevant aspects. Based on an analysis done by National Pharmaceuticals Pricing Authority, the Department of Pharmaceuticals submitted its comments to Shri Arun Maira committee. In this, we have Stated that it would be reasonable to conclude that there is no substantive factual proof for increase in prices of drugs due to acquisitions.

(b) and (c) The Department of Industrial Policy and Promotion who are nodal Department of Foreign Direct Investment (FDI), has informed that the policy for allowing FDI, upto 100% in existing companies, in the Pharmaceuticals sector, under the Government approval route, was introduced *vide* Press Note 3 of 2011, dated 08.11.2011. This provision has since been incorporated under "Circular 1 of 2012–Consolidated FDI Policy", effective from 10.04.2012.

#### **Import of active pharmaceutical ingredients**

2370. DR. JANARDHAN WAGHMARE: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) the details and status of various issues till date that have been deliberated by the Inter Ministers Committee formed as per recommendations of the 45th Report of Parliamentary Standing Committee on Health;

(b) whether it is a fact that more than 80 per cent of active pharmaceutical ingredients are being imported from China by the Indian Pharmaceutical Industry; and

(c) the steps taken by Government to upgrade the infrastructure, documentation as per WHO and Good Manufacturing Practices (GMP) of the Small and Medium Pharmaceutical industry?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI SRIKANT JENA): (a) No Inter Ministers Committee was formed as per the recommendations of the 45th Report of Parliamentary Standing Committee on Health. However, a High Powered Inter-Ministerial Coordination Committee formed by the Department of Pharmaceuticals under the Chairmanship of Secretary (Pharmaceuticals) to look into the matters of implementation of Government commitment to provide quality medicines at affordable prices has finalized its recommendations. The various recommendations of the Committee pertaining to the

pricing and quality aspects of medicines have been referred to the concerned Ministries/ Departments/Organizations for taking necessary action.

(b) Ministry of Commerce and Industries has clarified that Indian pharmaceutical Industry has been importing Active Pharmaceutical Ingredients (APIs) and Intermediates from various countries, including China to meet the increasing demand. Details of imports of APIs and Intermediates by Indian Pharmaceutical industry for the last 3 years are given below:

(Values in US\$ mn)

	2009-10	2010-11	2011-12 (upto Feb 2012)
Total imports from Global	2406	2998	3069
Imports from China	1143	1881	1646
%age of China imports out of total imports	60%	64%	54%

(c) Ministry of Micro, Small and Medium Enterprises (MSME) is supporting SME Units in Pharmaceutical Sector through various schemes - Credit Link Capital Subsidy Scheme (CLCSS) to provide incentive to Micro and Small Enterprises for technology upgradation, Credit Guarantee Scheme, ISO-9000/ISO-14001/HACCP reimbursement scheme, Micro and Small Enterprises - Cluster Development Programme (MSE-CDP), Public Procurement Policy for Micro and Small Enterprises and National Manufacturing Competitive Programme (NMCP) to enhance their productivity and Competitiveness. In regard of Drug and Pharmaceuticals 294 units have availed Rs. 19.76 crore subsidy since inception of the scheme.

#### **Availability of essential medicines at fair prices**

†2371. SHRI BHAGAT SINGH KOSHYARI: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether differences/anomalies in the prices of essential medicines have been found at large scale in the country;

(b) if so, the details thereof and the reasons therefor;

---

†Original notice of the question was received in Hindi.